HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marketing in Brief: Clinique Smudgecicles

This article was originally published in The Rose Sheet

Executive Summary

Clinique Smudgecicles: "Silky...pearlized texture" of the firm's new color eye pencils "glides on with creamy ease" while the pencils dry to a matte finish, the Estee Lauder division said. The eye pencils use volatile silicone technology to provide color that "stays put, without creasing, smudging or fading" and is maintenance free, Clinique said. Available in eight shades, the retractable pencils will be on counters in May for $12.50. The company's Superlast lipstick will also be available in May. The lipstick's breakthrough formula "marries long wear with pampering comfort," Clinique claims. The product soothes and protects with jojoba oil and aloe and contains the "treatment complex" (wheat sphingolipid, green olive extract and vitamin E) found in the company's All About Lips. Available now, the lipstick retails for $12.50...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS005168

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel